Overcoming Challenges in Infectious Diseases
Discover the latest medical research on the prevention, management and treatment of infectious diseases.
LATEST TOPICS
-
Estimated cardiac risk associated with macrolides and fluoroquinolones decrease substantially when adjusted for patient characteristics18 July, 2018Researchers at the University of Iowa discovered a decrease in cardiac risk associated with macrolides and fluoroquinolones – when underlying patient characteristics and conditions related to... -
More than 100 persons infected with E. coli O157:H7 in the United State18 July, 2018An outbreak of Escherichia coli O157:H7 linked to romaine lettuce from the Yuma growing region in Arizona has spread to 35 states in the United States, bringing the total cases to 197 as of 1... -
Sitafloxacin demonstrated 100% Chlamydia trachomatis eradication rate among male patients with urethritis in Japan25 June, 2018Chlamydia trachomatis is one of the most common causes of non-gonococcal urethritis in men.1 Treatment options for chlamydia urethritis include tetracyclines, macrolides and fluoroquinolones.... -
E-cigarette vapour may increase risk for pneumonia22 June, 2018The use of electronic cigarettes (e-cigarettes) or ‘vaping’ has been marketed as a safer alternative to tobacco cigarette smoking and as a potential smoking cessation tool. However, recent... -
Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef)21 June, 2018Question HAP, VAP, and HCAP – Definition and mechanisms Q01 Defining HAP, VAP, and HCAP Q02 Incidence of HAP, VAP, and HCAP Q03 Mechanisms involved in... -
The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode)21 June, 2018Question AECB - Defining the diagnosis Q01 Defining AECB Q02 Epidemiological profile of AECB Antimicrobial therapy for... -
Effect of Combination of Levofloxacin and Meropenem against Pseudomonas aeruginosa (Supervised by Prof. Kazuhiro Tateda, MD, PhD)21 June, 2018The pathogen Pseudomonas aeruginosa causes a variety of respiratory tract infections which are normally treated with antipseudomal drugs. However, some of these infections fail to respond... -
Viewing Infectious Respiratory Disease (Supervised by Prof. Jiro Fujita, MD, PhD, ACCP)21 June, 2018Viewing Infectious Respiratory Disease begins by examining bacterial secondary infection following influenza virus infections. Influenza patients can develop secondary infections,... -
The Role of Levofloxacin for the Treatment of Respiratory Tract Infections (Highlights of a Special Roundtable Discussion)21 June, 2018Introduction Pharmacodynamics and Pharmacokinetics of Levofloxacin George L. Drusano, MD Professor and Director Division of Clinical Pharmacology Departments of Medicine... -
New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation (Highlights of the Daiichi Pharmaceutical Co., Ltd. Satellite Symposium to the 11th International Congress on Infectious Diseases)21 June, 2018Introduction Comparative Antimicrobial Susceptibility of Respiratory Tract Pathogens David Felmingham, BSc MSc Dip LSHTM Chief Executive , GR Micro Ltd, London,...
CONTENT LIBRARY
CONTENT LIBRARY
INTERVIEWS
-
Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef)
-
The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode)
-
Effect of Combination of Levofloxacin and Meropenem against Pseudomonas aeruginosa (Supervised by Prof. Kazuhiro Tateda, MD, PhD) -
Viewing Infectious Respiratory Disease (Supervised by Prof. Jiro Fujita, MD, PhD, ACCP)
-
New Challenges for Levofloxacin in the Fight Against Infectious Diseases (Interviews with World-Renowned Experts) -
New Era for the Treatment of Respiratory Tract infections (Daiichi Pharmaceutical Co., Ltd., Special Interview) -
The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia (Interview with Prof. Thomas M. File, Jr, MD, MS ) -
Smarter Therapy: Guidelines for Optimal Management of Neutropenic Cancer Patients (Interview with Professor Thomas M. File, Jr.) -
Levofloxacin in the Medical Management of Community-acquired Pneumonia (Interview with Prof. Andy I. M. Hoepelman) -
The Way Forward: High-Dose, Short-Course Levofloxacin Leads the Field
UPCOMING EVENTS
02 August - 04 August, 2018
Philadelphia, PA, USA, North America
19 August - 24 August, 2018
Daegu, Korea, Asia Pacific
23 August - 26 August, 2018
Copenhagen, Denmark, Western Europe
